
June 15 (Reuters) - Incyte Corp INCY.O:
POSITIVE LATE-BREAKING DATA FOR INCYTE’S FIRST-IN-CLASS MUTCALR-TARGETED THERAPY INCA033989 IN ESSENTIAL THROMBOCYTHEMIA PRESENTED AT EHA2025
INCYTE CORP - INCA033989 SHOWS POTENTIAL TO MODIFY DISEASE BY TARGETING MUTCALR CELLS
INCYTE CORP - 86% OF HIGH-RISK ET PATIENTS ACHIEVED HEMATOLOGIC RESPONSE WITH INCA033989
INCYTE CORP - 89% OF PATIENTS SHOWED REDUCTION IN MUTCALR VARIANT ALLELE FREQUENCY
INCYTE CORP - ONLY ONE PATIENT DISCONTINUED TREATMENT DUE TO TEAES